Overview

Clinical Trial to Assess the Safety and Pharmacokinetics of DA-2802 319mg and Viread 300mg in Healthy Male Volunteers

Status:
Completed
Trial end date:
2016-03-08
Target enrollment:
Participant gender:
Summary
This Phase I clinical study is to evaluate the safety and pharmacokinetics of DA-2802 319mg and Viread 300mg after a single oral dose in healthy male volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Dong-A ST Co., Ltd.
Treatments:
Tenofovir